BioSig Technologies (OTCPK:BSGM) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BSGM 주식 개요

의료 기술 회사인 바이오시그 테크놀로지스는 심장 박동을 시작으로 신체의 전기 신호를 해독하는 데 주력하고 있습니다.

BSGM 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	2/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

보상

수익은 연간 160.63% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 4.5% 증가했습니다.

위험 분석

마이너스 주주 지분

지난 1년 동안 주주가 크게 희석되었습니다.

수익이 1백만 달러 미만인 경우 ( $27K )

의미 있는 시가총액이 없습니다. ( $5M )

+ 2 더 많은 위험

BioSig Technologies, Inc. 경쟁사

Aethlon Medical

NasdaqCM:AEMD

US$6.9m

ReShape Lifesciences

NasdaqCM:RSLS

US$4.5m

Heart Test Laboratories

NasdaqCM:HSCS

US$3.4m

Encision

OTCPK:ECIA

US$5.0m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 BioSig Technologies
과거 주가
현재 주가	US$0.35
52주 최고치	US$15.50
52주 최저치	US$0.20
베타	0.84
11개월 변경	-82.59%
3개월 변경 사항	-48.22%
1년 변경 사항	-97.03%
33년 변화	-99.16%
5년 변화	-99.61%
IPO 이후 변화	-99.56%

최근 뉴스 및 업데이트

Recent updates

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Dec 12

Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why

Dec 14

주주 수익률

	BSGM	US Medical Equipment	US 마켓
7D	1.1%	-0.9%	0.5%
1Y	-97.0%	-2.6%	20.5%

수익률 대 산업: BSGM 지난 1년 동안 -0.5 %를 반환한 US Medical Equipment 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: BSGM 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is BSGM's price volatile compared to industry and market?
BSGM volatility
BSGM Average Weekly Movement	46.3%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	2.8%

안정적인 주가: BSGM 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: BSGM 의 주간 변동성은 지난 1년 동안 30% 에서 49% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
2009	4	Anthony Amato	www.biosig.com

의료 기술 회사인 바이오시그 테크놀로지스는 심장 박동을 시작으로 신체의 전기 신호를 해독하는 데 주력하고 있습니다. 이 회사는 전례 없는 심장 신호 선명도를 제공하여 혼합 신호와 선 사이의 판독에 대한 의존을 종식시킵니다. 이 회사의 제품인 퓨어 EP 플랫폼은 실시간 신호 시각화를 제공하여 의사가 시술 효율성과 효능을 높인 표적 심장 절제술을 수행할 수 있도록 지원합니다.

BioSig Technologies, Inc. 기본 사항 요약

BioSig Technologies 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BSGM 기본 통계
시가총액	US$4.97m
수익(TTM)	-US$25.25m
수익(TTM)	US$27.00k

183.9x

P/S 비율

-0.2x

P/E 비율

BSGM 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BSGM 손익 계산서(TTM)
수익	US$27.00k
수익 비용	US$0
총 이익	US$27.00k
기타 비용	US$25.28m
수익	-US$25.25m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.78
총 마진	100.00%
순이익 마진	-93,529.63%
부채/자본 비율	-11.9%

BSGM 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

BSGM 주식 개요

보상

위험 분석

BioSig Technologies, Inc. 경쟁사

NasdaqCM:AEMD

US$6.9m

NasdaqCM:RSLS

US$4.5m

NasdaqCM:HSCS

US$3.4m

OTCPK:ECIA

US$5.0m

가격 내역 및 성능

최근 뉴스 및 업데이트

Nasdaq Hearings Panel Determines to Delist BioSig Technologies' Common Stock

BioSig Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.000005 million.

BioSig Technologies, Inc. announced delayed 10-Q filing

BioSig Technologies Regains Compliance with the Minimum Bid Price Requirements in Listing Rule 5550(a)(2)

BioSig Technologies, Inc. Appoints Anthony Amato as Chief Executive Officer

BioSig Technologies, Inc. announced delayed annual 10-K filing

Recent updates

Nasdaq Hearings Panel Determines to Delist BioSig Technologies' Common Stock

BioSig Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.000005 million.

BioSig Technologies, Inc. announced delayed 10-Q filing

BioSig Technologies Regains Compliance with the Minimum Bid Price Requirements in Listing Rule 5550(a)(2)

BioSig Technologies, Inc. Appoints Anthony Amato as Chief Executive Officer

BioSig Technologies, Inc. announced delayed annual 10-K filing

BioSig Technologies Receives Letter from Nasdaq Regarding No Longer Meets the Requirement of Rule 5550(b)(2)

BioSig Technologies Receives a Letter from the Listing Qualifications Department of Nasdaq Stating That the Company Has Not Regained Compliance with the Rule

Biosig Technologies, Inc. Announces Resignation of Kenneth L. Londoner as Chief Executive Officer

BioSig Announces Reduction of its Workforce

Biosig Technologies, Inc. Commences Workforce Reduction Consisted of the Departure of Sixteen Employees

BioSig Technologies, Inc. announced that it expects to receive $1.04 million in funding

BioSig Technologies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Market Value of Listed Securities

Consensus revenue estimates decrease by 67%, EPS upgraded

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $2.5 million.

BioSig Technologies, Inc. has filed a Follow-on Equity Offering.

BioSig Technologies, Inc. has filed a Follow-on Equity Offering.

Biosig Technologies, Inc. Appoints Fred Hrkac as Executive Vice President

BioSig Technologies, Inc., Annual General Meeting, Dec 18, 2023

BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $0.13464 million.

BioSig Technologies, Inc. announced that it has received $0.597497 million in funding

Price target increased by 27% to US$5.63

Consensus revenue estimates decrease by 24%

BioSig Technologies, Inc. announced that it has received $0.549999 million in funding

BioSig Technologies, Inc. Achieves Infrastructure and Technology Progress in Development of Generative AI Platform for Hospitals

Biosig Technologies, Inc. Introduces New Subscription Model for Pure Ep™ Platform, Offering Quicker Access to Latest Features, Customers

Biosig Technologies, Inc.'s Pure Ep Platform Debuts New Automated Features in First Patient Cases

Second quarter 2023 earnings released: US$0.16 loss per share (vs US$0.15 loss in 2Q 2022)

New minor risk - Share price stability

BioSig Technologies, Inc. Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare

Price target increased by 8.0% to US$4.50

Consensus EPS estimates fall by 24%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 65%, EPS upgraded

BioSig Technologies, Inc. Announces Chief Financial Officer Changes

BioSig Technologies, Inc. announced that it has received $1.299999 million in funding

BioSig Technologies, Inc. announced that it expects to receive $0.159998 million in funding

BioSig Technologies, Inc. announced that it expects to receive $1.299999 million in funding

BioSig's PURE EP(TM) System Demonstrates Potential Time and Cost Savings At the 15th APHRS Scientific Session in Singapore

Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why

BioSig Technologies Receives a Letter from the Nasdaq Stock Market

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$4.17

BioSig Technologies, Inc., Annual General Meeting, Dec 20, 2022

BioSig Technologies Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

BioSig in acquisition pact with San Antonio Hospital for cardiac signal system

BioSig Technologies, Inc. Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

BioSig: No Changes To Hold Thesis Following Q2 Earnings

Consensus forecasts updated

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSig Technologies Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 55%

BioSig signs purchase deal with Kansas City's Overland Park Regional hospital

BioSig: PURE EP Economics Trade Exhausted

BioSig Technologies, Inc.’s PURE EP™ System to be Featured During EPLive 2022

Consensus revenue estimates fall by 18%